Replies to post #192964 on NorthWest Biotherapeutics Inc (NWBO)

[Etienne1]

I think he meant blended data instead of unblinding twice.

[Evaluate]

Smith wrote:

What key opinion leaders have seen from observing the unblinded data is that DCVax-L seems to have a clinically meaningful survival tail. If so, it could become part of standard of care in newly diagnosed glioblastoma and could be a commercial blockbuster.

New data on the phase 3 trial will likely come in the form of another look at the unblinded data as was done before. I think that this will be a dramatic event and it could come in the time that I am not around. The Company has been working on this for some time and in the process is scrubbing the data from the various sites, which will be necessary for the regulatory submission.

1. If the trial is still blinded, is it feasible that Key Opinion Leaders have observed unblinded data .... or did he mean to indicate that the KOL’s have studied the BLINDED data?
2. Did Smith intend to state that NWBO will provide another look at BLINDED data as was done before ... ie a Spring 2018 Refresh similar to Spring 2017 Refresh?

[Ultraz2]

Thanks Larry Smith...though, as we, you are operating blind too without word from the company. Are your comments suppose to be official word from the company regarding the information you provided. Otherwise, how do you know if any of it’s true?

[Pablosrv]

Exciting times might be coming.

[JTORENCE]

Tilt what do you think he means by this statement (highlighted)?

New data on the phase 3 trial will likely come in the form of another look at the unblinded data as was done before. I think that this will be a dramatic event and it could come in the time that I am not around.